Intercept Pharmaceuticals Inc ICPT announced initial results from a planned interim analysis of its ongoing Phase 2 study 747-213, an active comparator trial demonstrating the therapeutic potential of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback